Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) fell 6% during trading on Tuesday . The stock traded as low as $4.95 and last traded at $4.99, with a volume of 240,731 shares changing hands. The stock had previously closed at $5.31.

Several brokerages have recently commented on ARGS. Zacks Investment Research lowered Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a research note on Tuesday, June 14th. Finally, Roth Capital raised their target price on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, April 19th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $11.84.

The company’s market cap is $129.20 million. The firm has a 50 day moving average of $5.86 and a 200 day moving average of $5.72.

Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. On average, analysts anticipate that Argos Therapeutics Inc. will post ($1.68) earnings per share for the current fiscal year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.